Company Filing History:

9 out of 525

Ludwig Institute for Cancer Research Limited

1 out of 832,891

Other

patents

Years Active: 2001-2011

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8080639 - Antibodies which bind specifically to activin receptor like kinase 3 (2011-12-20),

2. 7932351 - Activin receptor-like kinase-1 proteins having serine-threonine kinase domains (2011-04-26),

3. 7592428 - Antibodies which bind specifically to activin receptor like kinases (2009-09-22),

4. 7067260 - Methods of identifying morphogen receptor-binding analogs (2006-06-27),

5. 6982319 - Antibodies which bind specifically to activin receptor-like kinases (2006-01-03),

6. 6632618 - Morphogenic protein-specific cell surface receptors and uses therefor (2003-10-14),

7. 6605443 - Method for identifying compounds that affect Smad7 binding (2003-08-12),

8. 6331621 - Isolated nucleic acid molecules which encode activin-receptor like kinases, expression vectors and cells containing these (2001-12-18),

9. 6316217 - Activin receptor-like kinases, proteins having serine threonine kinase domains and polynucleotides encoding same (2001-11-13),

10. 6271365 - Activin like receptor--Isolated kinase proteins ALK-2, ALK-4, ALK-5, and nucleic acid molecules encoding them (2001-08-07),

11. 6207814 - Activin receptor-like kinases, ALK-3 and ALK-6, and nucleic acids encoding them (2001-03-27),

Title: The Innovations of Peter Ten Dijke

Introduction

Peter Ten Dijke is a prominent inventor based in Uppsala, Sweden. He has made significant contributions to the field of biotechnology, particularly in the area of receptor functionality. With a total of 11 patents to his name, his work has had a profound impact on diagnostic and therapeutic applications.

Latest Patents

Among his latest patents, Ten Dijke has developed antibodies that specifically bind to activin receptor-like kinase 3. This new receptor family has been identified as having activin-like kinase functionality, which is crucial for various diagnostic and therapeutic utilities. These novel proteins may possess a serine/threonine kinase domain, along with specific sequences in subdomain VIB and subdomain VIII. Additionally, he has patented activin receptor-like kinase-1 proteins that also exhibit serine-threonine kinase domains, further emphasizing the importance of this receptor family in medical research.

Career Highlights

Throughout his career, Peter Ten Dijke has worked with esteemed organizations such as the Ludwig Institute for Cancer Research Limited and Curis, Inc. His research has been pivotal in advancing our understanding of receptor functionality and its implications in health and disease.

Collaborations

Ten Dijke has collaborated with notable scientists in his field, including Carl-Henrik Heldin and Kohei Miyazono. These partnerships have fostered innovation and have contributed to the success of his research endeavors.

Conclusion

Peter Ten Dijke's work exemplifies the intersection of innovation and biotechnology. His patents and collaborations continue to influence the scientific community and pave the way for future advancements in medical research.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com